Factor V Leiden paradox: Risk of deep vein thrombosis but not of pulmonary embolism

Lancet

Volumn 356, Issue 9225, 2000, Pages 182-183

  Bounameaux, H ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; PROTHROMBIN; THROMBIN;

ACTIVATED PROTEIN C RESISTANCE; DEEP VEIN THROMBOSIS; GENE MUTATION; HUMAN; LUNG EMBOLISM; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0034661802     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02476-4     Document Type: Note

References (14)

1. RM Bertina BP Koeleman T Koster Mutation in blood coagulation factor V associated with resistance to activated protein C Nature 369 1994 64 67
2. B Dahlbäck M Carlsson PJ Svensson Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C : prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90 1993 1004 1008
3. B Dahlbäck Blood coagulation Lancet 335 2000 1627 1632
4. S Desmarais P de Moerloose G Reber P Minazio A Perrier H Bounameaux Resistance to activated protein C in an unselected population of patients with pulmonary embolism Lancet 347 1996 1345
5. B Manten RGJ Westendorp T Koster PH Reitsma FR Rosendaal Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation Thromb Haemost 76 1996 510 513
6. I Martinelli M Cattaneo D Panzeri PM Mannucci Low prevalence of factor V: Q506 in 41 patients with isolated pulmonary embolism Thromb Haemost 77 1997 440 443
7. TP Baglin K Brown D Williamson P Baker R Luddington Relative risk of pulmonary embolism and deep vein thrombosis in association with the factor V Leiden mutation in a United Kingdom population Thromb Haemost 77 1997 1219
8. F Turkstra R Karemaker PMM Kuijer MH Prins HR Büller Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different? Thromb Haemost 81 1999 345 348
9. de Moerloose P, Reber G, Perrier A, Perneger T, Bounameaux H. Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. Br J Haematol (in press).
10. Meyer G, Emmerich J, Helley D, et al. Prevalence of factor V Leiden and factor II 20210A in a large cohort of unselected patients with pulmonary embolism and/or deep vein thrombosis. Am J Med (in press).
11. S Ehrenforth M Krause FH Herrmann K Wulff B Zwinge Scharrer I. Pathogenesis of primary pulmonary embolism: impact of the factor XIII: val34leu polymorphism Haemostasis 30 2000 36 (abstr).
12. C van't Veer M Kalafatis RM Bertina P Simioni KG Mann Increased tissue factor initiates prothrombin activation as a result of the Arg506-Gln mutation in factor V Leiden J Biol Chem 272 1997 20721 20729
13. L Bajzar M Kalafatis P Simioni PB Tracy An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden J Biol Chem 271 1996 2949 2952
14. O Björgell PE Nilsson JA Nilsson PJ Svensson Location and extent of deep vein thrombosis in patients with and without FV: R506Q mutation Thromb Haemost 83 2000 648 651